Cholangiocarcinoma

December 15th 2022

Distal cholangiocarcinomas are rare, but clinicians can use a variety of imaging to diagnose it.

November 30th 2022

Only 2% of patients with primary sclerosing cholangitis (PSC) received a cholangiocarcinoma diagnosis, and the diagnosis was not early enough for there to be a survival benefit.

November 29th 2022

Investigators also confirmed that FGFR2 fusion–positive tumors have a higher expression of FGFR2 but were not associated with higher expression of FGFR1, FGFR3, or FGFR4.

November 25th 2022

There are currently 3 FDA-approved therapies to treat cholangiocarcinoma with FGFR2 fusion or rearrangement, but these therapies face the development of resistance. Studies are underway to identify ways to overcome this resistance.